PITTSBURGH, Nov. 8, 2010 /PRNewswire/ -- D3 Radiation Oncology Solutions announced that it has completed collaborative commissioning of two Varian TrueBeam medical linear accelerators at the John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, N.J.
The TrueBeam system, which Varian designed to treat a moving target with unprecedented speed and accuracy, features technical innovations to dynamically synchronize imaging, patient positioning, motion management, and treatment delivery. With its High Intensity Mode, TrueBeam offers faster, more efficient and more precise radiotherapy for cancer treatment. The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, and research of all types of cancer. After TrueBeam was installed by Varian, D3 physicists commissioned it for clinical use.
"D3 Radiation Oncology Solutions was an easy choice for assisting us with our Varian TrueBeam commissioning project," said Alois M. Ndlovu, Ph.D., acting director of medical physics, John Theurer Cancer Center, Hackensack University Medical Center. "D3 has an earned and well-deserved reputation for quality work."
"The collaborative commissioning and data modeling process with D3 was comprehensive and efficient," said Mehmet Tuna, director of radiation oncology, John Theurer Cancer Center, Hackensack University Medical Center.
"Commissioning a TrueBeam system must take into account that many TrueBeam installations could have as many as six photon energies, whereas most conventional linear accelerators have two," said Ron Lalonde, Ph.D., DABR, chief scientific officer, D3 Radiation Oncology Solutions. "The High Intensity Mode beams are new, so centers have to learn what these beams ought to look like. And small field measurement, with appropriate small detectors and precise setup of measurements, is critical for TrueBeam, especially for stereotactic radiosurgery."
The John Theurer Cancer Center at Hackensack University Medical CenterThe John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancer. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of after care services that distinguish the John Theurer Cancer Center from other facilities. For more information please visit to humccancer.org.
D3 Radiation Oncology SolutionsD3 Radiation Oncology Solutions has been a trusted source of technical expertise and industry knowledge in radiation oncology since 2001. D3 solutions have been developed with leading experts through its affiliation with UPMC and UPMC Cancer Centers. D3 offers the solutions practices need today for success tomorrow and delivers them with unmatched expertise proven over a decade. From flexible options for commissioning and treatment planning to pathways and other tools and programs that support clinical quality, D3 solutions accelerate excellence in radiation oncology. For more information, please access D3's website at www.d3rad.com or call (412) 365-0710.
TrueBeam is a trademark of Varian Medical Systems, Inc.Media ContactsD3:Andrew Bailey - 412-365-0744 - email@example.comUPMC:
Wendy Zellner - 412-586-9777 - firstname.lastname@example.org
|SOURCE D3 Radiation Oncology Solutions|
Copyright©2010 PR Newswire.
All rights reserved